Outlook Therapeutics (OTLK) Operating Leases (2019 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Operating Leases of $156958.0 for Q1 2026, down 28.32% year-over-year from $218961.0 in Q1 2025, and down 8.74% quarter-over-quarter from $171988.0 in Q4 2025.
Outlook Therapeutics (OTLK) Operating Leases (2019 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Operating Leases for 8 consecutive years, with $156958.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Leases fell 28.32% year-over-year to $156958.0; the TTM figure through Mar 2026 stood at $156958.0 (down 28.32% YoY), while the FY2025 annual figure was $188801.0, down 23.54% from the prior year.
- Operating Leases declined to $156958.0 in Q1 2026 per OTLK's latest filing, from $171988.0 in the prior quarter.
- Across five years, Operating Leases topped out at $260395.0 in Q2 2024 and bottomed at $3929.0 in Q1 2023.
- Historically, Operating Leases has averaged $139621.8 across 5 years, with a median of $171988.0 in 2025.
- Annual changes were most pronounced in 2023 — Operating Leases sank 92.0% — and 2025, when it dropped 21.6%.
- Outlook Therapeutics' Operating Leases stood at $15573.0 in 2022, then sank by 74.77% to $3929.0 in 2023, then soared by 5833.14% to $233113.0 in 2024, then fell by 26.22% to $171988.0 in 2025, then decreased by 8.74% to $156958.0 in 2026.
- Business Quant data shows OTLK's Operating Leases at $156958.0 in Q1 2026, $171988.0 in Q4 2025, and $188801.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 156,958.00 |
| Dec 31, 2025 | 171,988.00 |
| Sep 30, 2025 | 188,801.00 |
| Jun 30, 2025 | 204,145.00 |
| Mar 31, 2025 | 218,961.00 |
| Dec 31, 2024 | 233,113.00 |
| Sep 30, 2024 | 246,922.00 |
| Jun 30, 2024 | 260,395.00 |
| Mar 31, 2023 | 3,929.00 |
| Dec 31, 2022 | 15,573.00 |
| Sep 30, 2022 | 26,995.00 |
| Jun 30, 2022 | 38,203.00 |
| Mar 31, 2022 | 49,100.00 |
| Dec 31, 2021 | 59,584.00 |
| Sep 30, 2021 | 69,849.00 |
| Jun 30, 2021 | 79,923.00 |
| Sep 30, 2020 | 187,486.00 |
| Jun 30, 2020 | 48,394.00 |
| Mar 31, 2020 | 95,747.00 |
| Dec 31, 2019 | 142,129.00 |